At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome
In Brief
A Phase 2 clinical trial evaluating Tofacitinib for Down Syndrome and 5 related conditions. Completed, enrolled 47 participants across 1 site.
Detailed Summary
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions. The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adolescents and adults with DS and an autoimmune and/or autoinflammatory skin condition. Investigators will also measure the impact of interferon inhibition on a variety of molecular markers, as well as the cognitive abilities and quality of life of participants.
Study Details
Timeline
Interventions
Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome